Summit Therapeutics/$SMMT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
$SMMT
Sector
Primary listing
Employees
159
Headquarters
Website
SMMT Metrics
BasicAdvanced
$13B
-
-$1.25
-1.14
-
Price and volume
Market cap
$13B
Beta
-1.14
52-week high
$36.91
52-week low
$15.55
Average daily volume
3.4M
Financial strength
Current ratio
3.796
Quick ratio
3.674
Long term debt to equity
1.408
Total debt to equity
2.823
Interest coverage (TTM)
-103,901.44%
Profitability
EBITDA (TTM)
-934.964
Management effectiveness
Return on assets (TTM)
-152.88%
Return on equity (TTM)
-292.50%
Valuation
Price to book
69.97
Price to tangible book (TTM)
70.7
Price to free cash flow (TTM)
-49.524
Free cash flow yield (TTM)
-2.02%
Free cash flow per share (TTM)
-0.365
Growth
Earnings per share change (TTM)
349.52%
3-year earnings per share growth (CAGR)
16.56%
What the Analysts think about SMMT
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
Bulls say / Bears say
Summit is negotiating with AstraZeneca to license its investigational lung cancer drug ivonescimab in a deal that could be worth up to $15 billion, reflecting strong partnership interest and the possibility of significant non-dilutive funding (Reuters).
Ivonescimab showed a favorable overall survival trend in late-stage studies in combination with chemotherapy, suggesting the therapy may offer meaningful clinical advantages over current treatments (Reuters).
Summit closed Q2 2025 with $297.9 million in cash, cash equivalents, and short-term investments, giving it financial resources to fund its global Phase III trials through mid-2026 (Reuters via Tiger Brokers).
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.
SMMT Financial Performance
Revenues and expenses
SMMT Earnings Performance
Company profitability
SMMT News
AllArticlesVideos
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Business Wire1 week ago
Why Wall Street Is Backing These 3 Comeback Stocks
MarketBeat1 week ago
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Summit Therapeutics stock?
Summit Therapeutics (SMMT) has a market cap of $13B as of November 07, 2025.
What is the P/E ratio for Summit Therapeutics stock?
The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of November 07, 2025.
Does Summit Therapeutics stock pay dividends?
No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Summit Therapeutics dividend payment date?
Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Summit Therapeutics?
Summit Therapeutics (SMMT) has a beta rating of -1.14. This means that it has an inverse relation to market volatility.